[1/2] FILE PHOTO-Dutch technology company Philips' logo is seen at company headquarters in Amsterdam, Netherlands, January 29, 2019. REUTERS/Eva Plevier/File Photo Acquire Licensing RightsAMSTERDAM, Oct 6 (Reuters) - The U.S. Food and Drug Administration (FDA) said it is still not satisfied with how Dutch healthcare technology company Philips (PHG.AS) has handled a major product recall and the company should conduct additional risk testing. It was the latest blow to Philips over the recall of millions of sleep apnea and respiratory devices, which has been ongoing since 2021. Philips lost more than two-thirds of its market valuation in 2021-2022, but has staged a modest recovery in 2023. "The FDA is clearly still not happy with the way the recall is being handled."

---

Persons: Eva Plevier, Philips, Bernstein, Toby Sterling, Piotr Lipinski, Mark Potter, Jan Harvey Organizations: Philips, REUTERS, Rights, U.S . Food, Drug Administration, FDA, Thomson Locations: Amsterdam, Netherlands, U.S